Bile Duct Cancer Market - Rising Prevalence of Cancer & Demand for New Treatment Accelerate the Growth of the Market

Pune, India, December, 2017/MRFR Press Release/- Market Research Future published a Half Cooked research report on “Global  Bile Duct Cancer Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

Bile Duct Cancer Market-Overview

Bile duct cancer is a rare type of neoplasm in which epithelial cells of the bile duct are mutated and show epithelial differentiation. Bile duct cancer be diagnosed using blood tests, abdominal imaging, surgery, and others.

According to the National Cancer Institute, in 2014, there were an estimated 66,771 cases of intrahepatic bile duct cancer in the U.S. Moreover, the disease is expected to cause 28,920 deaths by the end of 2017 accounting for 4.8% of all cancer deaths. Death rates have been rising on average 2.6% each year over 2005-2014. Such an increasing prevalence of the bile duct cancer will boost the market during the forecast period. Moreover, rising healthcare expenditure, increasing awareness for the disease, and investments in the R&D for treatment procedures is fuelling the market growth.

However, high cost of treatment and related side effects along with low healthcare expenditures in the developing economies is expected restrain the market growth during the forecast period.

According to the Centres for Disease Control and Prevention (CDC), U.S. health care spending in 2015, reached USD 3.2 trillion or USD 9,990 per person which accounted for 17.8% of the total GDP. Moreover, the presence of the global market leaders like Pfizer Inc. and Bristol-Myers Squibb Company within the region fuels the market growth during the forecasted period.

Key Players in the Bile Duct Cancer market:

Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd (Europe), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd. (Isreal), Eli Lilly and Company. (U.S.), Sanofi (France), Fresenius Kabi AG (Germany), Mylan N.V. (U.S.), and others. 

Key Developments:

Strategic approaches adopted help the major players in the market to sustain their growth and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players.

Pfizer Inc.:

Pfizer Inc. is an American global pharmaceutical corporation headquartered in New York City.  It is among the world's largest pharmaceutical companies. Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology/endocrinology, and neurology. Anti-malaria drugs developed by the company include Metakelfin, Camoquin and Dualkin.

• December 2017: Pfizer Inc. and Basilea Pharmaceutica Ltd., a biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, entered into an agreement in which Pfizer will grant the exclusive development and commercialization rights in China and several countries in the Asia Pacific region to CRESEMBA (isavuconazole). CRESEMBA is a novel antifungal medicine for the treatment of adult patients with diagnosed invasive aspergillosis and mucormycosis1, resulting in mortality among patients with HIV and cancer. The rights for distribution and commercialization of CRESEMBA in sixteen Asian Pacific countries and China (including Hong Kong and Macao) will lay with Pfizer, excluding Japan. Furthermore, Pfizer will be responsible for marketing authorization holder for the Asia Pacific Region and China.


• July 2017: Pfizer completed an agreement with Basilea to obtain the exclusive commercialization rights to CRESEMBA in Europe (with the exception of the Nordic countries). Since that time, Pfizer has assumed responsibility for the commercialization of CRESEMBA in Austria, France, Germany, Italy, and the United Kingdom and successfully launched CRESEMBA in Spain with additional launches expected in 2018 and beyond.

Teva Pharmaceutical Industries ltd:

• 
  July, 2017: Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Vagifem 1 (estradiol vaginal inserts), 10 mcg in the U.S. it is indicated for the treatment of atrophic vaginitis due to menopause. This adds to the company’s more than 70 products in women’s health segment. The launch will help the company to expand portfolio of oral contraceptives and hormone replacement therapies providing range of products for women health. 

• July, 2017: Teva Pharmaceutical Industries Ltd. announced the launch of generic Epiduo 1 (adapalene and benzoyl peroxide) gel, 0.1%/2.5% in the U.S. Adapalene and benzoyl peroxide gel are indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. This launch will help the company to strengthen it market in the U.S. and maintain product diifertiation.


• 
  September, 2016: Teva Pharmaceutical Industries ltd signed a multi-project alliance agreement with Cancer Research Technology Ltd. (CRT), U.K to develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells. DDR will protect cancer cells from the damaging effect of chemotherapy. 

Browse Full Report @ https://www.marketresearchfuture.com/reports/bile-duct-cancer-market-4741